FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All Resources2024 US Conference – Sponsorship and Exhibitor Overview
Topic: Conference
Presentation
Free
GCSG Presentation Tips from Steve Jacobs
Topics: Communication, Personal Development
Conference Training
Members
Pelican webinar - Impact of COVID-19 on Cold Chain
Topics: Cold Chain, Supply Chain
Webinar
Free
